Imagen de Portada

Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer

Guardado en:
Publicado en:NPJ Breast Cancer vol. 10, no. 1 (2024), p. 28
Autor principal: Morganti, Stefania
Otros Autores: Jin, Qingchun, Vincuilla, Julie, Buehler, Ryan, Ryan, Sean, Stokes, Samantha, Parker, Tonia, Mittendorf, Elizabeth A., King, Tari A., Weiss, Anna, Partridge, Ann H., Bychkovsky, Brittany L., Curigliano, Giuseppe, Tayob, Nabihah, Lin, Nancy U., Garber, Judy E., Tolaney, Sara M., Lynce, Filipa
Publicado:
Nature Publishing Group
Materias:
Genetic testing
Oncology
Tumors
Surgery
Cancer therapies
Chemotherapy
Breast cancer
Acceso en línea:Citation/Abstract
Full Text - PDF
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Resumen:Following the survival benefit demonstrated in the OlympiA trial, one year of adjuvant olaparib is now recommended for all patients with germline BRCA1/2 pathogenic/likely pathogenic variants (PV) and high-risk, HER2-negative early breast cancer after chemotherapy. However, optimal identification of high-risk patients who may derive benefit from this genomically-directed therapy is debated. In this study, we sought to characterize the real-world proportion of gBRCA1/2 PV carriers eligible for adjuvant olaparib according to the OlympiA criteria, and to compare clinicopathologic characteristics and outcomes between eligible and ineligible patients.
ISSN:2374-4677
DOI:10.1038/s41523-024-00632-8
Fuente:Health & Medical Collection